Skip to main content
Top
Published in: Abdominal Radiology 12/2021

01-12-2021 | Nephrectomy | Kidneys, Ureters, Bladder, Retroperitoneum

Association between nuclear grade of renal cell carcinoma and the aorta-lesion-attenuation-difference

Authors: Joseph R. Grajo, Nikhil V. Batra, Shahab Bozorgmehri, Laura L. Magnelli, Padraic O’Malley, Russell Terry, Li-Ming Su, Paul L. Crispen

Published in: Abdominal Radiology | Issue 12/2021

Login to get access

Abstract

Introduction and background

Several features noted on renal mass biopsy (RMB) can influence treatment selection including tumor histology and nuclear grade. However, there is poor concordance between renal cell carcinoma (RCC) nuclear grade on RMB compared to nephrectomy specimens. Here, we evaluate the association of nuclear grade with aorta-lesion-attenuation-difference (ALAD) values determined on preoperative CT scan.

Methods and materials

A retrospective review of preoperative CT scans and surgical pathology was performed on patients undergoing nephrectomy for solid renal masses. ALAD was calculated by measuring the difference in Hounsfield units (HU) between the aorta and the lesion of interest on the same image slice on preoperative CT scan. The discriminative ability of ALAD to differentiate low-grade (nuclear grade 1 and 2) and high-grade (nuclear grade 3 and 4) tumors was evaluated by sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under curve (AUC) using ROC analysis. Sub-group analysis by histologic sub-type was also performed.

Results

A total of 368 preoperative CT scans in patients with RCC on nephrectomy specimen were reviewed. Median patient age was 61 years (IQR 52–68). The majority of patients were male, 66% (243/368). Tumor histology was chromophobe RCC in 7.6%, papillary RCC in 15.5%, and clear cell RCC in 76.9%. The majority, 69.3% (253/365) of tumors, were stage T1a. Nuclear grade was grade 1 in 5.46% (19/348), grade 2 in 64.7% (225/348), grade 3 in 26.2% (91/348), and grade 4 in 3.2% (11/348). Nephrographic ALAD values for grade 1, 2, 3, and 4 were 73.7, 46.5, 36.4, and 43.1, respectively (p = 0.0043). Nephrographic ALAD was able to differentiate low-grade from high-grade RCC with a sensitivity of 32%, specificity of 89%, PPV of 86%, and NPV of 36%. ROC analysis demonstrated the predictive utility of nephrographic ALAD to predict high- versus low-grade RCC with an AUC of 0.60 (95% CI 0.51–0.69).

Conclusion

ALAD was significantly associated with nuclear grade in our nephrectomy series. Strong specificity and PPV for the nephrographic phrase demonstrate a potential role for ALAD in the pre-operative setting that may augment RMB findings in assessing nuclear grade of RCC. Although this association was statistically significant, the clinical utility is limited at this time given the results of the statistical analysis (relatively poor ROC analysis). Sub-group analysis by histologic subtype yielded very similar diagnostic performance and limitations of ALAD. Further studies are necessary to evaluate this relationship further.
Literature
18.
go back to reference Dhyani M, Grajo JR, Rodriguez D, et al. (2017) Aorta-Lesion-Attenuation-Difference (ALAD) on contrast-enhanced CT: a potential imaging biomarker for differentiating malignant from benign oncocytic neoplasms Abdom Radiol 42:1734–1743. https://doi.org/10.1007/s00261-017-1061-3. Dhyani M, Grajo JR, Rodriguez D, et al. (2017) Aorta-Lesion-Attenuation-Difference (ALAD) on contrast-enhanced CT: a potential imaging biomarker for differentiating malignant from benign oncocytic neoplasms Abdom Radiol 42:1734–1743. https://​doi.​org/​10.​1007/​s00261-017-1061-3.
20.
go back to reference Grajo JR, Batra NV, Bozorgmehri S, et al. (2021) Validation of aorta–lesion–attenuation difference on preoperative contrast-enhanced computed tomography scan to differentiate between malignant and benign oncocytic renal tumors. Abdom Radiol. https://doi.org/10.1007/s00261-021-02971-7. Online ahead of print. Grajo JR, Batra NV, Bozorgmehri S, et al. (2021) Validation of aorta–lesion–attenuation difference on preoperative contrast-enhanced computed tomography scan to differentiate between malignant and benign oncocytic renal tumors. Abdom Radiol. https://​doi.​org/​10.​1007/​s00261-021-02971-7. Online ahead of print.
23.
go back to reference Rossi SH, Prezzi, D, Kelly-Morland C, et al. (2018) Imaging for the diagnosis and response assessment of renal tumours. World J Urol 36, 1927–1942 (2018). https://doi-org.lp.hscl.ufl.edu/https://doi.org/10.1007/s00345-018-2342-3 Rossi SH, Prezzi, D, Kelly-Morland C, et al. (2018) Imaging for the diagnosis and response assessment of renal tumours. World J Urol 36, 1927–1942 (2018). https://​doi-org.​lp.​hscl.​ufl.​edu/​https://​doi.​org/​10.​1007/​s00345-018-2342-3
40.
go back to reference Kahn AE, Lomax, SJ, Bajalia EM, et al. (2020) Utility of the Aortic-Lesion-Attenuation-Difference (ALAD) and Peak Early-Phase Enhancement Ratio (PEER) to differentiate benign from malignant renal masses. Can J Urol 27(4):10278-10284.PubMed Kahn AE, Lomax, SJ, Bajalia EM, et al. (2020) Utility of the Aortic-Lesion-Attenuation-Difference (ALAD) and Peak Early-Phase Enhancement Ratio (PEER) to differentiate benign from malignant renal masses. Can J Urol 27(4):10278-10284.PubMed
Metadata
Title
Association between nuclear grade of renal cell carcinoma and the aorta-lesion-attenuation-difference
Authors
Joseph R. Grajo
Nikhil V. Batra
Shahab Bozorgmehri
Laura L. Magnelli
Padraic O’Malley
Russell Terry
Li-Ming Su
Paul L. Crispen
Publication date
01-12-2021
Publisher
Springer US
Published in
Abdominal Radiology / Issue 12/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-021-03260-z

Other articles of this Issue 12/2021

Abdominal Radiology 12/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.